LabGenius Therapeutics has teamed up with Sanofi again. This collaboration will speed up the discovery and improvement of NANOBODY molecules. They will combine LabGenius’ AI/ML antibody design platform with Sanofi’s expertise in NANOBODY® development. The renewed partnership builds on past success. It will use LabGenius’ EVA™ platform to co-optimize NANOBODY® candidates. This effort focuses on new inflammation-related targets. The goal is to enhance key therapeutic properties. They will do this using machine learning and high-throughput testing. This partnership shows a shift in the industry. It focuses on data-driven antibody engineering.
Also Read: Southwire and Orange Charger Announces Partnership
AI is being used more to tackle tough protein optimization problems that traditional methods find hard to solve. “We are truly excited about this new collaboration with Sanofi,” said LabGenius’ CSO, Dr. Angus Sinclair. “This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients.” The alliance merges computational design and advanced biologics expertise. This partnership allows both companies to accelerate the development of next-gen therapeutics. Their goals include improved precision, quicker results, and increased clinical potential.